Furthermore, analysis of patients’ overall survival (OS) revealed that in addition to ACC, KIRP, LGG, LIHC, MESO, PAAD, SARC, and SKCM patients with a poor prognosis (similar to the disease-free survival model), LUAD (p < 0.001) patients also had a poor survival with the overexpression of RACGAP1 (Figure S1). Here, RACGAP1 is linked to pancreatic adenocarcinoma.